Recent Updates — PASW
Shareholders approved a 40-for-one share consolidation taking effect on October 23, 2026, reducing the number of Class A and Class B ordinary shares by that ratio. The company also increased authorized share capital to US$12.5 million and adopted new articles of association. Additionally, shareholders granted authority for future reverse splits ranging from 10-for-1 to 80-for-1 if the stock price falls below specified thresholds over consecutive trading days. Ping An Biomedical Co., Ltd. operates in the biomedical industry.
Ping An Biomedical Co., Ltd. entered into a non-binding letter of intent with Future Biotechnology Group Co., Limited on October 22, 2026, to acquire three tumor cell-related medical technology patents covering oncology diagnosis and treatment, cell detection, bioengineering, and biomarker technologies for consideration ranging from US $2 million to US $2.5 million. The transaction is subject to due diligence and the execution of a definitive agreement. Management intends to incorporate these assets into its healthcare technology IP reserve to support long-term biomedical R&D strategies, though it does not expect near-term material revenue generation. Ping An Biomedical Co., Ltd. operates as an apparel supply chain management service provider while expanding into healthcare and biomedical technologies.
Shareholders are being asked to ratify a 40-for-one share consolidation effective October 23, 2026, and approve an increase in authorized share capital from US$312,500 to US$12.5 million. The filing also outlines conditional further consolidations ranging from 10-to-1 up to 80-to-1 if the stock price falls below specified thresholds. Ping An Biomedical Co., Ltd. operates in the biomedical and healthcare sector.
Ping An Biomedical Co., Ltd. announced on August 5, 2026, that its board resolved not to reappoint WWC, P.C. as its independent registered public accounting firm, effective immediately. The company has engaged Edston Global PAC as its new auditor, effective August 6, 2026. There were no disagreements with the former auditor regarding accounting principles or financial disclosures during their tenure since 2020. This change in auditors is a material event for investors assessing governance and audit quality. The company operates in the biomedical industry.
Ping An Biomedical Co., Ltd. signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd. to expand product channels and market outreach. The partnership aims to achieve cumulative sales of RMB 500 million within three years by leveraging Yuan Sheng Mei Yan's health management and wellness services network. Ping An Biomedical operates in the biotechnology and healthcare products industry.